We are live on ! Find out more
CLOS

Compagnie Lombard Odier SCmA Portfolio holdings

AUM $9.25B
1-Year Est. Return 27.04%
This Fund
S&P 500
This Quarter Est. Return
+9.36%
1 Year Est. Return
+27.04%
3 Year Est. Return
+108.78%
5 Year Est. Return
+129.43%
10 Year Est. Return
+503.05%
AUM
$4.55B
AUM Growth
+$12.4M
Cap. Flow
-$345M
Cap. Flow %
-7.59%
Top 10 Hldgs %
40.84%
Holding
720
New
73
Increased
111
Reduced
146
Closed
92

Top Buys

Rank Stock Value
1
CRM icon
Salesforce
CRM
+$46.3M
2
BLK icon
Blackrock
BLK
+$25.5M
3
SE icon
Sea Limited
SE
+$21.7M
4
NOW icon
ServiceNow
NOW
+$21.2M
5
EL icon
Estee Lauder
EL
+$19M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$22M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$20.4M
3
APLS
Apellis Pharmaceuticals
APLS
+$19.4M
4
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M
5
TXG icon
10x Genomics
TXG
+$17.9M

Sector Composition

Rank Sector Weight
1 Technology 19.67%
2 Communication Services 18.56%
3 Financials 15.44%
4 Consumer Discretionary 14.23%
5 Healthcare 14.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
676
Twist Bioscience
TWST
$7.25B
– –
-106,859
Closed -$13.2M
TXG icon
677
10x Genomics
TXG
$6.61B
– –
-98,783
Closed -$17.9M
UAA icon
678
Under Armour
UAA
$2.6B
– –
-3,000
Closed -$66K
VGK icon
679
Vanguard FTSE Europe ETF
VGK
$31.1B
– –
-700
Closed -$44K
VRSK icon
680
Verisk Analytics
VRSK
$25B
– –
-6,091
Closed -$1.08M
WFC icon
681
CALL
Wells Fargo
WFC
$264B
– –
-1,000
Closed -$12K
YMAB
682
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-181,492
Closed -$5.49M
YSG
683
Yatsen Holding
YSG
$319M
– –
-3,560
Closed -$220K
ZBRA icon
684
Zebra Technologies
ZBRA
$17.8B
– –
-1,250
Closed -$606K
NKLA
685
DELISTED
Nikola Corporation Common Stock
NKLA
– –
-4
Closed -$2K
RCM
686
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-238,178
Closed -$5.88M
GTHX
687
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-601,591
Closed -$14.5M
FSR
688
DELISTED
Fisker Inc.
FSR
– –
-48,000
Closed -$709K
GOEV
689
DELISTED
Canoo Inc. Class A Common Stock
GOEV
– –
-27
Closed -$114K
MDRX
690
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-839,521
Closed -$12.6M
IMGN
691
DELISTED
Immunogen Inc
IMGN
– –
-1,849,772
Closed -$15M
MRTX
692
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-43,428
Closed -$7.44M
TRHC
693
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
– –
-344,334
Closed -$15.9M
MAXR
694
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
– –
-100
Closed -$3.56K
NVCN
695
DELISTED
Neovasc Inc.
NVCN
$0 ﹤0.01%
3
– –
SGFY
696
DELISTED
Signify Health, Inc.
SGFY
– –
-180,734
Closed -$5.29M
RUBY
697
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-163,172
Closed -$4.39M
CTXS
698
DELISTED
Citrix Systems Inc
CTXS
– –
-430
Closed -$60K
CERN
699
DELISTED
Cerner Corp
CERN
– –
-600
Closed -$46.2K
DRNA
700
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-526,058
Closed -$13.5M
25 26 27
28
29

Similar funds

SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $9.18B AUM 25.04% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Compagnie Lombard Odier SCmA's Q2 2021 Portfolio in Review

As of Q2 2021, Compagnie Lombard Odier SCmA held 720 positions worth $4.55B, up 0.27% from $4.54B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Compagnie Lombard Odier SCmA withdrew a net $345M in Q2 2021, closing 92 positions and reducing 146 holdings. Its most notable exit was Allogene Therapeutics, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 16% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Compagnie Lombard Odier SCmA opened a new position in Bilibili worth $9.73M.

  • Compagnie Lombard Odier SCmA's largest Q2 2021 buy was Bilibili: 79,851 shares worth $9.73M.
  • Compagnie Lombard Odier SCmA added most to Salesforce in Q2 2021, an estimated $46.3M increase.
  • Compagnie Lombard Odier SCmA's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $22M.
  • Compagnie Lombard Odier SCmA fully exited Allogene Therapeutics in Q2 2021, selling an estimated $18.9M.
  • Compagnie Lombard Odier SCmA's ten largest holdings make up 41% of its $4.55B portfolio in Q2 2021.
  • Compagnie Lombard Odier SCmA opened 73 new positions and closed 92 in Q2 2021.
  • Compagnie Lombard Odier SCmA's portfolio value rose 0.27% quarter-over-quarter to $4.55B.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.